{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T15:02:52Z","timestamp":1790434972728,"version":"4.1.0"},"reference-count":49,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:00:00Z","timestamp":1771545600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Psychodermatology encompasses the complex relationship between psychiatric disorders and dermatologic conditions, focusing on their bidirectional effects. This review delves into the role of psychopharmacology in managing dermatologic diseases and their associated psychiatric comorbidities, specifically investigating how psychotropic medications, such as antidepressants, anxiolytics, and antipsychotics, are used to treat dermatologic conditions with psychiatric comorbidities and their impact on both skin health and psychiatric symptoms. A narrative review was conducted, synthesizing studies published between 2019 and 2024 that included studies focused on psychopharmacological interventions in psychocutaneous disorders. Relevant literature was analyzed to evaluate the efficacy of psychotropic medications in improving both dermatologic and psychiatric symptoms. The present review highlighted that psychotropic medications, particularly antidepressants, anxiolytics, and antipsychotics, offer significant benefits in managing psychodermatologic conditions. Across the literature, antidepressants were shown to reduce inflammation and immune dysregulation in conditions such as psoriasis and hidradenitis suppurativa. Furthermore, psychotropic drugs were shown to alleviate psychiatric symptoms associated with dermatologic diseases, such as anxiety, compulsive behaviors, and delusional thoughts. Although the literature has demonstrated the efficacy of psychotropic medication in treating dermatologic diseases, psychiatric referrals and psychopharmacological treatments remain underutilized in clinical practice. Psychopharmacology plays a crucial role in managing psychodermatologic conditions by addressing both skin and psychiatric symptoms. Despite growing evidence of the importance and utility of psychodermatology, there is a need for greater awareness and incorporation of multidisciplinary psychiatric evaluation and treatment in dermatologic care. Future research should focus on larger, longitudinal studies to assess the long-term efficacy and safety of psychotropic medications in dermatology.<\/jats:p>","DOI":"10.4103\/idoj.idoj_186_25","type":"journal-article","created":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T13:00:15Z","timestamp":1771592415000},"page":"178-184","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Psychopharmacology in Dermatology"],"prefix":"10.4103","volume":"17","author":[{"given":"Olivia","family":"Katamanin","sequence":"first","affiliation":[{"name":"Chicago Medical School, Rosalind Franklin University, North Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheila","family":"Sharifi","sequence":"additional","affiliation":[{"name":"Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6358-9068","authenticated-orcid":false,"given":"Mohammad","family":"Jafferany","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, Central Michigan University College of Medicine, Mount Pleasant, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,2,20]]},"reference":[{"key":"R1-20260303","doi-asserted-by":"crossref","first-page":"383","DOI":"10.31887\/DCNS.2006.8.4\/ssmith","article-title":"The role of the hypothalamic-pituitary-adrenal axis in neuroendocrine responses to stress","volume":"8","author":"Smith","year":"2006","journal-title":"Dialogues Clin Neurosci"},{"key":"R2-20260303","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.3390\/ijms18102131","article-title":"Association between stress and the HPA axis in the atopic dermatitis","volume":"18","author":"Lin","year":"2017","journal-title":"Int J Mol Sci"},{"key":"R3-20260303","doi-asserted-by":"crossref","first-page":"13030\/qt8949296f","DOI":"10.5070\/D3262047430","article-title":"The role of hypothalamus-pituitary-adrenal (HPA)-like axis in inflammatory pilosebaceous disorders","volume":"26","author":"Saric-Bosanac","year":"2020","journal-title":"Dermatol Online J"},{"key":"R4-20260303","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1007\/s00424-013-1284-2","article-title":"New insights into the mechanisms of itch:Are pain and itch controlled by distinct mechanisms?","volume":"465","author":"Liu","year":"2013","journal-title":"Pflugers Arch"},{"key":"R5-20260303","doi-asserted-by":"crossref","first-page":"303","DOI":"10.4103\/cdr.cdr_10_22","article-title":"Introduction to psychodermatology","volume":"7","author":"Latheef","year":"2023","journal-title":"Clin Dermatol Rev"},{"key":"R6-20260303","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S0893-133X(98)00088-8","article-title":"Negative immunoregulatory effects of antidepressants: Inhibition of interferon-g and stimulation of interleukin-10 secretion","volume":"20","author":"Maes","year":"1999","journal-title":"Neuropsychopharmacology"},{"key":"R7-20260303","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.ijwd.2018.05.002","article-title":"Implementation of a psychodermatology clinic at a major health system in Detroit","volume":"4","author":"Seale","year":"2018","journal-title":"Int J Womens Dermatol"},{"key":"R8-20260303","doi-asserted-by":"crossref","first-page":"e13557","DOI":"10.1111\/dth.13557","article-title":"Psychopharmacology in dermatology:Treatment of primary psychiatric conditions in dermatology","volume":"33","author":"Torales","year":"2020","journal-title":"Dermatol Ther"},{"key":"R9-20260303","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.ad.2014.10.010","article-title":"Psychotropic drugs in dermatology","volume":"106","author":"Rodr\u00edguez Mart\u00edn","year":"2015","journal-title":"Actas Dermosifiliogr"},{"key":"R10-20260303","doi-asserted-by":"crossref","first-page":"307","DOI":"10.4103\/idoj.IDOJ_330_19","article-title":"Update on pharmacotherapy in psychodermatological disorders","volume":"11","author":"Shenoi","year":"2020","journal-title":"Indian Dermatol Online J"},{"key":"R11-20260303","doi-asserted-by":"crossref","first-page":"566","DOI":"10.36849\/JDD.7181","article-title":"Neurogenic rosacea treatment: A literature review","volume":"22","author":"Ivanic","year":"2023","journal-title":"J Drugs Dermatol"},{"key":"R15-20260303","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.clindermatol.2018.08.006","article-title":"Use of antipsychotic drugs in dermatology","volume":"36","author":"Gupta","year":"2018","journal-title":"Clin Dermatol"},{"key":"R17-20260303","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.3390\/biomedicines10123281","article-title":"Seventy years of treating delusional disorder with antipsychotics: A historical perspective","volume":"10","author":"Gonz\u00e1lez-Rodr\u00edguez","year":"2022","journal-title":"Biomedicines"},{"key":"R18-20260303","doi-asserted-by":"crossref","first-page":"144","DOI":"10.5114\/ada.2019.88464","article-title":"Delusional infestation in clinical practice over a period of two decades","volume":"38","author":"Reszke","year":"2019","journal-title":"Adv Dermatol Allergol Dermatol Alergol"},{"key":"R19-20260303","doi-asserted-by":"crossref","first-page":"e122","DOI":"10.1002\/ski2.122","article-title":"Delusional infestation in healthcare professionals: Outcomes from a multi-centre case series","volume":"2","author":"Frewen","year":"2022","journal-title":"Skin Health Dis"},{"key":"R20-20260303","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1111\/jdv.20081","article-title":"Efficacy of antipsychotics in delusional infestation","volume":"39","author":"Tang","year":"2025","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R21-20260303","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1093\/ced\/llad326","article-title":"Delusional infestation: A retrospective cohort study of 49 patients over a 6-year period","volume":"49","author":"Hutchison","year":"2024","journal-title":"Clin Exp Dermatol"},{"key":"R22-20260303","first-page":"160","article-title":"Delusional parasitosis (Ekbom syndrome) \u2013 A psychodermatologic disorder","volume":"108","author":"Stroynowska-Kosik","year":"2021","journal-title":"Dermatol Rev\/Przegl Dermatol"},{"key":"R23-20260303","first-page":"794","article-title":"Aripiprazole as a treatment option for delusional parasitosis: Case series of 8 patients","volume":"29","author":"\u00c7\u0131nar","year":"2019","journal-title":"Psychiatry Clin Psychopharmacol"},{"key":"R24-20260303","doi-asserted-by":"crossref","first-page":"S317","DOI":"10.1192\/j.eurpsy.2021.851","article-title":"Successful treatment of primary delusional parasitosis with paroxetine: A case report and narrative review","volume":"64","author":"Delgado","year":"2021","journal-title":"Eur Psychiatry"},{"key":"R25-20260303","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1155\/MI.2005.273","article-title":"Serum levels of TNF-alpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity","author":"Arican","year":"2005","journal-title":"Mediators Inflamm. 2005"},{"key":"R26-20260303","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/164_2018_166","article-title":"Role of inflammation in depression and treatment implications","volume":"250","author":"Felger","year":"2019","journal-title":"Handb Exp Pharmacol"},{"key":"R27-20260303","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1111\/jdv.14460","article-title":"Depression and suicidality in psoriasis:Review of the literature including the cytokine theory of depression","volume":"31","author":"Koo","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R28-20260303","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/mp.2016.167","article-title":"Antidepressant activity of anti-cytokine treatment: A systematic review and meta-analysis of clinical trials of chronic inflammatory conditions","volume":"23","author":"Kappelmann","year":"2018","journal-title":"Mol Psychiatry"},{"key":"R29-20260303","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.jad.2020.09.108","article-title":"Major depressive disorder increased risk of psoriasis: A propensity score matched cohort study","volume":"278","author":"Chen","year":"2021","journal-title":"J Affect Disord"},{"key":"R30-20260303","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1111\/bjd.14032","article-title":"Risk of depression in women with psoriasis: A cohort study","volume":"173","author":"Dommasch","year":"2015","journal-title":"Br J Dermatol"},{"key":"R31-20260303","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.jad.2020.11.110","article-title":"Protective effects of anti-depressants against the subsequent development of psoriasis in patients with major depressive disorder: A cohort study","volume":"281","author":"Tzeng","year":"2021","journal-title":"J Affect Disord"},{"key":"R32-20260303","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/joim.12093","article-title":"Use of serotonin reuptake inhibitors in patients with psoriasis is associated with a decreased need for systemic psoriasis treatment: A population-based cohort study","volume":"274","author":"Thorslund","year":"2013","journal-title":"J Intern Med"},{"key":"R33-20260303","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.bbi.2019.02.021","article-title":"Effects of SSRIs on peripheral inflammatory markers in patients with major depressive disorder: A systematic review and meta-analysis","volume":"79","author":"Wang","year":"2019","journal-title":"Brain Behav Immun"},{"key":"R34-20260303","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1001\/jamadermatol.2019.0759","article-title":"Depression and anxiety in adults with hidradenitis suppurativa: A systematic review and meta-analysis","volume":"155","author":"Machado","year":"2019","journal-title":"JAMA Dermatol"},{"key":"R35-20260303","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/jdv.12567","article-title":"Psychiatric comorbidities in 3207 patients with hidradenitis suppurativa","volume":"29","author":"Shavit","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R36-20260303","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1111\/j.1365-2133.2011.10254.x","article-title":"Elevated levels of tumour necrosis factor (TNF)-\u03b1, interleukin (IL)-1\u03b2 and IL-10 in hidradenitis suppurativa skin: A rationale for targeting TNF-\u03b1 and IL-1\u03b2","volume":"164","author":"van der Zee","year":"2011","journal-title":"Br J Dermatol"},{"key":"R37-20260303","doi-asserted-by":"crossref","first-page":"adv00376","DOI":"10.2340\/00015555-3737","article-title":"Risk of hidradenitis suppurativa comorbidities over time: A prospective cohort study of Danish blood donors","volume":"101","author":"Andersen","year":"2021","journal-title":"Acta Derm Venereol"},{"key":"R38-20260303","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2340\/00015555-0554","article-title":"Itch and mental distress: A cross-sectional study among late adolescents","volume":"89","author":"Halvorsen","year":"2009","journal-title":"Acta Derm Venereol"},{"key":"R39-20260303","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s40257-020-00534-y","article-title":"Emerging therapeutic options for chronic pruritus","volume":"21","author":"Reszke","year":"2020","journal-title":"Am J Clin Dermatol"},{"key":"R40-20260303","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.jaci.2018.09.005","article-title":"Itch: From mechanism to (novel) therapeutic approaches","volume":"142","author":"Yosipovitch","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"R41-20260303","doi-asserted-by":"crossref","first-page":"2274291","DOI":"10.1080\/09546634.2023.2274291","article-title":"Gabapentin and oral antidepressants for chronic pruritus: A prospective cohort study evaluating efficacy and side effects in daily dermatological practice","volume":"34","author":"Kouwenhoven","year":"2023","journal-title":"J Dermatol Treat"},{"key":"R42-20260303","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.jaci.2012.08.006","article-title":"Evaluation and management of a patient with chronic pruritus","volume":"130","author":"Steinhoff","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"R43-20260303","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2340\/00015555-0553","article-title":"Treatment of chronic pruritus with the selective serotonin re-uptake inhibitors paroxetine and fluvoxamine: Results of an open-labelled, two-arm proof-of-concept study","volume":"89","author":"St\u00e4nder","year":"2009","journal-title":"Acta Derm Venereol"},{"key":"R44-20260303","doi-asserted-by":"crossref","first-page":"885023","DOI":"10.3389\/fimmu.2022.885023","article-title":"Case report: Pemphigoid nodularis-five patients with many years of follow-up and review of the literature","volume":"13","author":"Szymanski","year":"2022","journal-title":"Front Immunol"},{"key":"R45-20260303","doi-asserted-by":"crossref","first-page":"624517","DOI":"10.3389\/fimmu.2021.624517","article-title":"Translational research in vitiligo","volume":"12","author":"Katz","year":"2021","journal-title":"Front Immunol"},{"key":"R46-20260303","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s40257-021-00631-6","article-title":"Psychosocial effects of vitiligo: A systematic literature review","volume":"22","author":"Ezzedine","year":"2021","journal-title":"Am J Clin Dermatol"},{"key":"R47-20260303","doi-asserted-by":"crossref","first-page":"1072837","DOI":"10.3389\/fmed.2023.1072837","article-title":"Beyond skin white spots: Vitiligo and associated comorbidities","volume":"10","author":"Hu","year":"2023","journal-title":"Front Med"},{"key":"R48-20260303","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/j.jaad.2018.11.047","article-title":"Vitiligo and major depressive disorder: A bidirectional population-based cohort study","volume":"80","author":"Vallerand","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"R49-20260303","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1001\/archdermatol.2010.413","article-title":"Neurogenic rosacea: A distinct clinical subtype requiring a modified approach to treatment","volume":"147","author":"Scharschmidt","year":"2011","journal-title":"Arch Dermatol"},{"key":"R50-20260303","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/1346-8138.15629","article-title":"Neurogenic rosacea in Korea","volume":"48","author":"Kim","year":"2021","journal-title":"J Dermatol"},{"issue":"(10 Suppl)","key":"R51-20260303","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1016\/j.amjmed.2009.04.007","article-title":"Treatment of neuropathic pain:An overview of recent guidelines","volume":"122","author":"O'Connor","year":"2009","journal-title":"Am J Med"},{"key":"R52-20260303","doi-asserted-by":"crossref","first-page":"74","DOI":"10.22159\/ajpcr.2021.v14i7.41872","article-title":"Comparison of pregabalin and nortriptyline on efficacy and safety in postherpetic neuralgia","author":"Khajuria","year":"2021","journal-title":"Asian J Pharm Clin Res"},{"key":"R53-20260303","doi-asserted-by":"crossref","first-page":"813","DOI":"10.2340\/00015555-3094","article-title":"Usefulness of psychiatric intervention in a joint consultation for the treatment of burning mouth syndrome: A monocentric retrospective study","volume":"99","author":"Le Bris","year":"2019","journal-title":"Acta Derm Venereol"}],"container-title":["Indian Dermatology Online Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/idoj.idoj_186_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:14:18Z","timestamp":1787166858000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/idoj.idoj_186_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,20]]},"references-count":49,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/idoj.idoj_186_25","relation":{},"ISSN":["2229-5178","2249-5673"],"issn-type":[{"value":"2229-5178","type":"print"},{"value":"2249-5673","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,20]]},"assertion":[{"value":"2025-02-17","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-07","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}